Autologous adipose-derived mesenchymal stem cell therapy reverses detrusor underactivity: open clinical trial

Detrusor underactivity is a disease that can cause chronic urinary tract infection, urinary tract infection, urinary retention and kidney failure and has no effective treatment in traditional medicine. The present research evaluated the effects of cell therapy with adipose tissue-derived stem cells...

Full description

Saved in:
Bibliographic Details
Published in:Stem cell research & therapy 2023-04, Vol.14 (1), p.64-64, Article 64
Main Authors: Coelho, Henrique Rodrigues Scherer, Neves, Silvia Cordeiro das, da Silva Menezes, Jovino Nogueira, Antoniolli-Silva, Andréia Conceição Milan Brochado, Oliveira, Rodrigo Juliano
Format: Article
Language:English
Subjects:
Adipose tissue
Adipose Tissue - cytology
Adipose tissues
Anesthesia
Bladder
Body fat
Cell therapy
Chronic infection
Clinical trials
Contractility
Diabetes
Health aspects
Humans
Intubation
Laboratories
Liposuction
Male
Mesenchymal Stem Cell Transplantation
Mesenchymal stem cells
Mesenchymal Stem Cells - cytology
Patients
Quality of Life
Questionnaires
Renal failure
Research ethics
Software
Stem cell research
Stem cells
Transplantation
Transplants & implants
Ultrasonic imaging
Urinary Bladder
Urinary Bladder Neck Obstruction
Urinary Bladder, Underactive - therapy
Urinary tract
Urinary tract infections
Urodynamics
Urogenital system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Detrusor underactivity is a disease that can cause chronic urinary tract infection, urinary tract infection, urinary retention and kidney failure and has no effective treatment in traditional medicine. The present research evaluated the effects of cell therapy with adipose tissue-derived stem cells on the treatment of detrusor underactivity in men. Nine male patients diagnosed with a clinical and urodynamic diagnosis of detrusor underactivity were evaluated and underwent two transplants via cystourethroscopy, with 2 × 10 cells/transplant, performed by intravesical injection at five points on the bladder body above the vesical trigone. Cell therapy increased the maximum flow from 7.22 ± 1.58 to 13.56 ± 1.17, increased the mean flow from 3.44 ± 0.74 to 5.89 ± 0.45, increased the urinated volume from 183.67 ± 49.28 to 304.78 ± 40.42 and reduced the residual volume in the uroflowmetry exam from 420.00 ± 191.41 to 118.33 ± 85.51; all of these changes were significant (p 
ISSN:1757-6512
1757-6512
DOI:10.1186/s13287-023-03294-8